Arena Pharmaceuticals, Inc.  

(Public, NASDAQ:ARNA)   Watch this stock  
Find more results for ARNA
4.14
0.00 (0.00%)
Nov 25 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.05 - 4.20
52 week 3.26 - 7.97
Open 4.15
Vol / Avg. 2.94M/4.01M
Mkt cap 906.89M
P/E     -
Div/yield     -
EPS -0.24
Shares 220.11M
Beta -0.41
Inst. own 50%
Jan 12, 2015
Arena Pharmaceuticals Inc at JPMorgan Healthcare Conference Add to calendar
Dec 2, 2014
Arena Pharmaceuticals Inc at Piper Jaffray Healthcare Conference - 8:30AM EST - Add to calendar
Nov 18, 2014
Arena Pharmaceuticals Inc at Stifel Healthcare Conference
Nov 12, 2014
Arena Pharmaceuticals Inc at Credit Suisse Healthcare Conference
Nov 3, 2014
Q3 2014 Arena Pharmaceuticals Inc Earnings Release
Nov 3, 2014
Q3 2014 Arena Pharmaceuticals Inc Earnings Call
Sep 26, 2014
Arena Pharmaceuticals Inc at BioCentury Publications NewsMakers in the Biotech Industry
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -130.72% -23.88%
Operating margin -321.03% -28.18%
EBITD margin - -18.10%
Return on average assets -13.56% -6.47%
Return on average equity -47.79% -20.40%
Employees 310 -
CDP Score - -

Address

6154 Nancy Ridge Drive
SAN DIEGO, CA 92121
United States - Map
+1-858-4537200 (Phone)
+1-858-4537210 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Arena Pharmaceuticals, Inc. (Arena) is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors. Its wholly owned subsidiary, Arena Pharmaceuticals GmbH (Arena GmbH), has granted Eisai Inc., rights to commercialize BELVIQ in the United States. The Company�s oral drug candidates include APD811, an agonist of the prostacyclin receptor intended for the treatment of pulmonary arterial hypertension, which is in Phase I; temanogrel, an inverse agonist of the serotonin 2A receptor intended for the treatment of thrombotic diseases, which has completed single- and multiple-ascending dose Phase I trials; APD334, an agonist of the S1P1 receptor intended for the treatment of autoimmune diseases, and APD371, an agonist of the cannabinoid receptor 2 intended for the treatment of pain, which is in preclinical development. In June 2012, the United States Food and Drug Administration approved its internally discovered drug, BELVIQ.

Officers and directors

Jack Lief Chairman of the Board, President, Chief Executive Officer
Age: 68
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Robert E. Hoffman Chief Financial Officer, Senior Vice President - Finance
Age: 48
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Dominic P. Behan Ph.D. Executive Vice President, Chief Scientific Officer, Director
Age: 50
Bio & Compensation  - Reuters
Steven W. Spector J.D. Executive Vice President, General Counsel, Secretary
Age: 49
Bio & Compensation  - Reuters
Craig M. Audet Senior Vice President - Operations and Head of Global Regulatory Affairs
Age: 50
Bio & Compensation  - Reuters
William R. Shanahan Jr., M.D., J.D. Senior Vice President, Chief Medical Officer
Age: 65
Bio & Compensation  - Reuters
Christine Anna White M.D. Lead Independent Director
Age: 62
Bio & Compensation  - Reuters
Donald D. Belcher Independent Director
Age: 75
Bio & Compensation  - Reuters
Scott H. Bice Independent Director
Age: 71
Bio & Compensation  - Reuters
Harry F. Hixson Jr., Ph.D. Independent Director
Age: 75
Bio & Compensation  - Reuters